

Liberalization of Coverage for Direct Acting Antivirals

Julie Sager, MD Medical Director Bureau of Benefits Management Division of Medicaid Services Wisconsin Department of Health Services

February 6, 2019

To protect and promote the health and safety of the people of Wisconsin.

Wisconsin Medicaid

- Wisconsin's state population is 5.8 million.
- 20% of Wisconsin's population is covered by Medicaid.
- About 80% of Wisconsin Medicaid is administered through health maintenance organizations.
- Pharmacy is a carved out benefit.

Cost Impact Projection

- Wisconsin worked with Milliman in 2015 to develop a financial model that could be used to predict cost of treating hepatitis C at various disease severity levels and various price points, which factored in cost savings from treatment.
- By this model, open access to direct acting antivirals (DAAs) were found to be cost prohibitive.

Pricing

- Leveraged preferred agents in negotiations with manufacturers.
- Discussed a buying partnership with other state agencies (Wisconsin Department of Employee Trust Funds and Department of Corrections).
- Found that regulatory constraints and market strategies across state partners were inherently different.

Pre-liberalization Policy

- Coverage was restricted to more severe disease; initially F3 or higher, then subsequently greater than or equal to F2
- Subspecialty prescribers (board certified gastroenterologists or infectious disease physician only)
- Sobriety restrictions

Stakeholder Input

- Iterative process
- Technical expertise regarding validated fibrosis measures and treatment of specific sub-populations
- Small changes were made over time

Market Forces

- More DAAs equals more leverage to negotiate supplemental rebates according to our preferred agents.
- In middle of 2017 Mayvret further disrupted the DAA market and was added as our preferred pan-genotypic agent.
- At this time, average price for course of DAAs had almost halved.

Changing Epidemiology

- Increasing hepatitis C infection in young people especially women
- Rate of births to Wisconsin Medicaid members with hepatitis C almost doubled from 2.7% in 2011 to 5.2% in 2015
- These women would generally not be meeting coverage criteria in the intrapartum period

Policy Change

- No disease severity restriction
- Any licensed prescriber
- Softer sobriety restrictions

Post Policy Change Utilization

- Examined 12m pre policy change vs. 12m post policy change
- Prior authorization requests increased only modestly by 17%
 - 12m pre policy change; 44% prior authorization denial rate equaled 466 members treated
 - 12m post policy change; denial rate was less than one percent and equaled 972 members treated

Fiscal Impact Post Policy Change

- Cost of increased utilization has been offset by reduced DAA prices.
 - Market forces offset the cost of increased utilization so that total expenditure was only modestly elevated post liberalization of coverage